Influence of low-carbohydrate diets on serum uric acid in patients with newly diagnosed type 2 diabetes mellitus

Influence of low-carbohydrate diets on serum uric acid in patients with newly diagnosed type 2 diabetes mellitus - Influence of low-carbohydrate diets on serum uric acid in patients with newly diagnosed type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042926

Enrollment

Registered

2021-01-06

Start date

2021-01-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients providing written informed consent to participate in the study 2.Aged >=20 years (irrespective of sex) 3.Serum uric acid level >6.0, <10.0 mg/dL at consent 4.A >0.5 mg/dL increase in serum uric acid level at consent compared to before that (2-6 weeks before consent)or serum uric acid level >=7.0 mg/dL both before and at consent 5.Patients who have not administration of drugs for hyperuricemia from at least 6 weeks before the date of consent 6.50% of total energy from carbohydrate and patients who have not intake barley at consent

Exclusion criteria

Exclusion criteria: 1.Type 1 diabetes 2.Patients with severe ketosis, diabetic coma or pre-coma, severe infection, perioperative, or severe trauma 3.Patients with severe renal dysfunction or treated with hemodialysis for end-stage renal disease 4.History of acute coronary syndrome, cerebrovascular disease, myocarditis, contractile pericarditis, or severe valvular disease within 12 weeks before consent 5.Patients with liver dysfunction (AST or ALT >100IU/L) or urolithiasis 6.Diagnosed or suspected malignant tumors (patients who do not have a treatment history of anticancer therapy within 1 year before consent, and have no plan to do so will not be excluded) 7.Pregnant, breast-feeding, or possibly pregnant women 8.Patients treated with SGLT2 inhibitor, losartan, or irbesartan within 6 weeks before consent 9.Patients in the study is judged by the investigator or sub-investigator as inappropriate for any other reason

Design outcomes

Primary

Measure	Time frame
Changes of serum uric acid and carbohydrate energy ratio at 12 weeks after barley intake	—

Secondary

Measure	Time frame
Changes of several parameters at 4, 8, and 12 weeks after barley intake as shown below	—

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Nakakinen clinic Department of clinical research

k-ofuchi@kensei-kai.com029-353-2800

Outcome results